← Back
Maxcyte
MXCT · listed on Nasdaq · worth $164.1 million
$1.59
−8.09% on Oct 30
No insider bought or sold Maxcyte stock on the market in the last year.
◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
93.7M shares
91% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
No insider bought or sold Maxcyte stock on the market in the last year. The reports below are share awards and other paperwork.
Big investors
People and funds that reported owning 5% or more of Maxcyte, newest first.
All reports
Every insider trade and SEC report we hold for Maxcyte.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
1 more with Pro →Analysts, earnings and news
Analysts' price target
$4.11 average
4 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 3 quarters above
Q4 '25−$0.06 a share+$0.03
Q3 '25−$0.09 a share+$0.01
Q2 '25−$0.12 a share−$0.02